News

From our CEO

19 December 2024

Rohan Greenland The May 50K

Tighten your seat belts. 2025 is going to be another big and productive year for MS Australia and the MS community. Highlights include:

Election: Our policy proposals have been developed and promoted to the major parties ahead of the federal election. We are calling for, inter alia:

  • A national MRFF neurological research mission
  • Funding for a national MS Biobank
  • A national MS nurse workforce strategy

Our advocacy will continue right through to polling day, whether it’s March, April or May.

Count Us In! As Chair of the Neurological Alliance Australia, I’m championing the Count Us In campaign to help get the attention, support and recognition that the seven million Australians living with neurological conditions need. You can bring the campaign to the attention of our politicians here.

PLATYPUS: Our new clinical trials seeking an effective medication for progressive forms of MS will enrol its first participant. This exciting adaptive clinical trial is supported by MSWA and is the Australian extension of the OCTOPUS clinical trial, funded by the UK MS Society and launched in April 2023.

Prevention: In April, we will partner with MS Canada to run an international workshop to help set an agenda for a multi-million dollar global prevention initiative with a focus on ultra-early detection and intervention to help stop MS before it starts.

Prevalence: We will release the latest report on the prevalence and economic impact of MS in Australia in late 2025. This eagerly anticipated report is currently being compiled by leading experts at the Menzies Institute for Medical Research.

Priorities: Early in the year, we will again be running our major research and advocacy priorities survey, so we can ensure all our work reflects the priorities that are important to you.

The May 50K: We are already in training for our biggest MS research fundraising event – The May 50K! I hope to hobble 200km for my May 50K, featuring two half-marathons, one in Sydney at the beginning of May, and one in the Arctic Circle on World MS Day – May 30. Get your teams ready – The May 50K is going to be big!

Neurological Data: Australia’s first-ever report on neurological disease data is expected mid-year in the form of a pilot report developed – following our advocacy – by the Australian Institute of Health and Welfare. A major milestone.

Conference: We are holding our biggest and best-ever research conference in Brisbane on December 3-5. Mark your diaries now!

Finally, a very big thank you to all our Member Organisations – MS Plus, MSWA, MS Queensland and MS SA/NT – our deeply committed Chair, George Pampacos, Deputy Chair Vicki Thomson, and all our Board Directors, our fabulous supporters, partners and donors, our amazing researchers, our hardworking staff and the wonderful, committed MS community.

Thank you and have a very happy Christmas

Related News

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

MS News

PBS access to two vital MS treatments under threat as Government decision looms

1 July 2026

Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

From our CEO